Evidence map›Paper›PMID 30559849›Full record

ArticleOpen access Macedonian journal of medical sciences2018

MicroRNA-150 down Regulation in Acute Myeloid Leukaemia Patients and Its Prognostic Implication.

Dalia A Abdelhalim, Basma M Elgamal, Mona R ElKafoury, Naglaa M Hassan, Marwa M Hussein, Mahmoud M Elhefnawi, Asmaa M Elfiky, Mohamed Nabil

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open access Macedonian journal of medical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Diagnostic and Prognostic Significance of serum miR-18a-5p in Patients with Atherosclerosis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Dalia A AbdelhalimDepartment of Clinical and Chemical Pathology, Medical Division, National Research Centre, Cairo, Egypt.
Basma M ElgamalDepartment of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt.
Mona R ElKafouryDepartment of Clinical and Chemical Pathology, Medical Division, National Research Centre, Cairo, Egypt.
Naglaa M HassanDepartment of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt.
Marwa M HusseinDepartment of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
Mahmoud M ElhefnawiInformatics and System Department, Engineering Research Division, National Research Centre, Cairo, Egypt.
Asmaa M ElfikyEnvironmental and Occupational Medicine Department, Environmental Research Division, National Research Centre, Cairo, Egypt.
Mohamed NabilDepartment of Clinical and Chemical Pathology, Medical Division, National Research Centre, Cairo, Egypt.
National Research Centre · EGCairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicroRNAs (miRNAs) are small, non-coding RNAs that are important for post-transcriptional gene regulation in both healthy and morbid conditions. Numerous miRNAs promote tumorigenesis, while others have a tumour suppressive effects. Acute myeloid leukaemia (AML) is a heterogeneous group of genetically diverse hematopoietic malignancies with variable response to treatment.

aimOur study aimed to investigate the possible role of miR-150 in de novo adult AML and the impact of its level on survival, and we used MATERIAL AND

methodsWe evaluated miR-150 expression profiling assay using TaqMan primer probes RT-PCR in the plasma of 50 adult AML patients, before the start of treatment and at day 28 of treatment, along with 20 normal adult control samples. miR-16 was used as an endogenous reference for standardisation. Follow-up of patients during treatment at day 28 of induction chemotherapy and after one year was done.

resultsIn this study, we found a significantly lower level of miR-150 in AML patients when compared to controls (p = 0.005) with 0.62 fold change than in healthy controls. Patients were divided into two groups: the low miR-150 group (miR-150 < 1) and the high miR-150 group (miR-150 > 1). A statistically significant difference was found between the two groups regarding initial total leukocytic count and initial PB blast count while for the TLC, HB and PLT count at follow up. No difference in the overall survival between the low and the high miR-150 groups could be demonstrated.

conclusionOur results suggest that miR-150 functions as a tumour suppressor and gatekeeper in inhibiting cell transformation and that its downregulation is required for leukemogenesis.

Indexed as

Acute myeloid leukaemiabiomarkersleukemogenesismicroRNAmiR-150

Identifiers

PMID30559849
PMCPMC6290449
OpenAlexW2902971594

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.